(Reuters) – Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage clinical trial.
Camizestrant, in combination with a standard of care agent designed to suppress proteins that spur tumour growth, showed improvement in the main goal of progression-free survival when given as a first-line treatment, the company said in its interim analysis.
AstraZeneca’s so-called “SERENA-6” trial was evaluating the combination for the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer with a type of genetic mutation.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry Jacob-Phillips)
